Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (30)

« Back to Publications

Upstream ORFs control TNFR1 abundance and tissue tolerance to TNF.

Ma B. et al, (2026), Science immunology, 11

Evidence of latent-lytic replication in EBV-positive Burkitt lymphoma from whole genome and transcriptome sequencing

Legason I. et al, (2025)

Unlocking cancer vaccine potential: What are the key factors?

Grant M. et al, (2024), Human vaccines & immunotherapeutics, 20

Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice.

McAuliffe J. et al, (2024), Journal for immunotherapy of cancer, 12

Genomic Landscape of Epstein-Barr Virus in Endemic Burkitt Lymphoma

Legason ID. et al, (2023), Blood, 142, 2985 - 2985

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression.

Ramirez-Valdez RA. et al, (2023), Cell reports, 42

Heterologous prime-boost viral vector cancer vaccines have protective effects against a syngeneic mouse model of glioblastoma

Steffke EE. et al, (2023), JOURNAL OF IMMUNOLOGY, 210

Heterologous primeboost viral vector vaccines for the treatment of a P1A-expressing BGL1 glioblastoma model

Steffke EE. et al, (2023), CANCER RESEARCH, 83

Human ZBP1 induces cell death-independent inflammatory signaling via RIPK3 and RIPK1.

Peng R. et al, (2022), EMBO reports, 23

Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC.

Leung CSK. and Van den Eynde BJ., (2022), Cancer cell, 40, 903 - 905

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.

McAuliffe J. et al, (2021), Journal for immunotherapy of cancer, 9

ZBP1 induces inflammatory signaling via RIPK3 and promotes SARS-CoV-2-induced cytokine expression

Peng R. et al, (2021)

Vaccination against the Epstein-Barr virus.

Rühl J. et al, (2020), Cellular and molecular life sciences : CMLS, 77, 4315 - 4324

Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.

Rühl J. et al, (2019), The Journal of clinical investigation, 129, 2071 - 2087

Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components.

Leung CS., (2018), Journal of immunology research, 2018

Load More